Class summary at a glance.

Every drug in the Skeletal Muscle Relaxant class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 3tracked in Part D
CY24 Part D spend: $221.1Mcombined across class
Total Rx claims: 21.7M8.1M unique beneficiaries
Generic mfrs (active): 37across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Tizanidine

Brand: Ontralfy · 10.6M Part D claims (CY24) · 3.6M beneficiaries · First FDA approval: 2002-07-03

18 generic mfrs 0 plans require PA

Low NADAC$0.031

→

Avg plan cost$0.056

Part D spend $117.4M 2× spread, current vs floor

Class share

53%

of class CY24 spend

View profile →

Cyclobenzaprine

Brand: AMRIX · 11.1M Part D claims (CY24) · 4.5M beneficiaries · First FDA approval: 2006-04-04

15 generic mfrs 361 plans require PA

Low NADAC$0.018

→

Avg plan cost$2.17

Part D spend $98.4M 122× spread, current vs floor

Class share

44%

of class CY24 spend

View profile →

Dantrolene

Brand: Dantrium · 66K Part D claims (CY24) · 12K beneficiaries · First FDA approval: 2005-03-01

4 generic mfrs 0 plans require PA

Low NADAC$0.410

→

Avg plan cost$0.542

Part D spend $5.4M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.